Crown Grows With Keri From GSK, Which Says Little On Consumer Pending JV Launch With Pfizer
Executive Summary
Sales to Crown Labs didn't breach GSK's attention when it reported its Q1 results, with its consumer health discussion limited to general figures on regions and product categories. Pfizer offered even less about its consumer health operations and plans with its Q1 report.For Crown Labs, landing North American rights to Keri brand marks another step toward offering comprehensive skin care selection.
You may also be interested in...
Crown To Acquire StriVectin, Appoint Its President Chief Commercial Officer
StriVectin president Cori Aleardi will join Crown’s executive leadership team, helping to merge the businesses and drive growth across Crown’s brand portfolio, which includes PanOxyl acne wash, Blue Lizard Australian Sunscreen, the SkinPen microneedling device, and prescription skin creams.
GSK Offloads Physiogel In North America, Asia To Korea’s LG
GSK will raise around £125m from the sale of skin-care brand Physiogel to LG Household & Healthcare to finance the integration of Pfizer Consumer Healthcare.
GSK Plans Further Divestments As Pfizer Brands Drive Up Q3 Sales
GSK is plotting further divestments into next year as it looks to focus its portfolio on key categories and raise funds to cover the costs of integrating Pfizer's Consumer Healthcare business. In the third quarter, GSK's sales advanced double-digits thanks to the inclusion of Pfizer megabrands like Advil and Centrum.